Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Q Ding, W Hu, R Wang, Q Yang, M Zhu, M Li… - Signal transduction and …, 2023 - nature.com
Rheumatoid arthritis (RA) is an incurable systemic autoimmune disease. Disease
progression leads to joint deformity and associated loss of function, which significantly …
progression leads to joint deformity and associated loss of function, which significantly …
JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects
The Janus kinase/signal transduction and activator of transcription (JAK–STAT) signaling
pathway is implicated in the pathogenesis of inflammatory and autoimmune diseases …
pathway is implicated in the pathogenesis of inflammatory and autoimmune diseases …
Spatial transcriptomics stratifies psoriatic disease severity by emergent cellular ecosystems
Whereas the cellular and molecular features of human inflammatory skin diseases are well
characterized, their tissue context and systemic impact remain poorly understood. We thus …
characterized, their tissue context and systemic impact remain poorly understood. We thus …
Selective JAKinibs: prospects in inflammatory and autoimmune diseases
AT Virtanen, T Haikarainen, J Raivola, O Silvennoinen - BioDrugs, 2019 - Springer
Cytokines, many of which signal through the JAK–STAT (Janus kinase–Signal Transducers
and Activators of Transcription) pathway, play a central role in the pathogenesis of …
and Activators of Transcription) pathway, play a central role in the pathogenesis of …
Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial
PJ Mease, DD Gladman, DH Collier… - Arthritis & …, 2019 - Wiley Online Library
Objective To examine the efficacy of methotrexate monotherapy relative to etanercept
monotherapy and the value of combining methotrexate and etanercept for the treatment of …
monotherapy and the value of combining methotrexate and etanercept for the treatment of …
Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce …
P Szulc, K Naylor, NR Hoyle, R Eastell, ET Leary… - Osteoporosis …, 2017 - Springer
Abstract Summary The National Bone Health Alliance (NBHA) recommends standardized
sample handling and patient preparation for C-terminal telopeptide of type I collagen (CTX-I) …
sample handling and patient preparation for C-terminal telopeptide of type I collagen (CTX-I) …
Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints
Psoriasis is a chronic systemic inflammatory disease causing erythematosus and scaly skin
plaques; up to 30% of patients with psoriasis develop Psoriatic Arthritis (PsA), which is …
plaques; up to 30% of patients with psoriasis develop Psoriatic Arthritis (PsA), which is …
Distinguishing rheumatoid arthritis from psoriatic arthritis
JF Merola, LR Espinoza, R Fleischmann - RMD open, 2018 - rmdopen.bmj.com
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) have key differences in clinical
presentation, radiographic findings, comorbidities and pathogenesis to distinguish between …
presentation, radiographic findings, comorbidities and pathogenesis to distinguish between …
Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study
A Ogdie, N Kay McGill, DB Shin… - European heart …, 2018 - academic.oup.com
Aims To determine the risk of venous thromboembolism (VTE) defined as the combined
endpoint of deep venous thrombosis (DVT) and pulmonary embolism (PE) among patients …
endpoint of deep venous thrombosis (DVT) and pulmonary embolism (PE) among patients …
Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients
Psoriatic arthritis (PsA) is a complex chronic musculoskeletal condition that occurs in~ 30%
of psoriasis patients. Currently, no systematic strategy is available that utilizes the …
of psoriasis patients. Currently, no systematic strategy is available that utilizes the …